Floatz Rating
CC44/100
Confidence
Indicative
Sponsor
Grünenthal GmbH
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07347548CT.gov A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male Participants | — | Active Not Recruiting | — | — | — |
NCT07317063CT.gov A Trial to Investigate Safety and Pharmacokinetics of GRT6019, Including Food Effect, in Healthy Male Participants | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Duchenne Muscular Dystrophy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| grt6019 (this asset) | Grünenthal GmbH | P1 | CC · 44 |
| Viltolarsen | NS Pharma, Inc. | P4 | BBB |
| Delandistrogene Moxeparvovec | Sarepta Therapeutics, Inc. | P3 | BB |
| Aoc 1044 | Avidity Biosciences, Inc. | P3 | BB |
| Golodirsen | Rare Disease Research, LLC | P4 | BB |
| Prednisolone | Anne M. Connolly | P4 | BB |
| Eteplirsen | Sarepta Therapeutics, Inc. | P3 | BB |
| Glutamine | Assistance Publique - Hôpitaux de Paris | P3 | BB |
| Vamorolone | Santhera Pharmaceuticals | P4 | BB |
+41 more in the Duchenne Muscular Dystrophy cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. grt6019 in Duchenne Muscular Dystrophy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/grt6019-duchenne-muscular-dystrophy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →